Mutations in the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) variants can compromise the effectiveness of therapeutic antibodies. Most clinical …

The emergence of SARS-CoV-2 variants that partially evade neutralizing antibodies poses a
threat to the efficacy of current COVID-19 vaccines,. The Ad26. COV2. S vaccine expresses …

Many studies have examined the impact of severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) variants on neutralizing antibody activity after they have become dominant …

Small number of SARS-CoV-2 epidemic lineages did not efficiently exhibit a neutralization
profile, while single amino acid mutation in the spike protein has not been confirmed in …

Summary The newly emerged BA. 2.75 severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) variant contains 9 additional mutations in its spike (S) protein compared to …

CD4+ T cells are essential for protection against viruses, including SARS-CoV-2. The
sensitivity of CD4+ T cells to mutations in SARS-CoV-2 variants of concern (VOCs) is poorly …

All current vaccines for COVID-19 utilize ancestral SARS-CoV-2 spike with the goal of
generating protective neutralizing antibodies. The recent emergence and rapid spread of …

INTRODUCTION Variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-
2) have been circulating worldwide since the beginning of the pandemic. Some are termed …

Background and Methods The SARS-CoV-2 (severe acute respiratory syndrome
coronavirus 2) Omicron (B. 1.1. 529) variant is the antigenically most distinct variant to date …

The globally circulating severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
variant of concern Omicron (B. 1.1. 529) has a large number of mutations, especially in the …